Zydus Lifesciences Share Price Watched as Company Gets Nod for Desidustat Phase III Sickle Cell Trial
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Zydus Lifesciences share price Rs 1,118.20, down 1.02 percent. Gets approval for 203-day Phase III trial of Desidustat in sickle cell disease with ICMR.
The Zydus Lifesciences share price was in focus on Thursday after the company received a key regulatory approval for a late stage clinical trial. Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease.
Click Here – Get Free Investment Predictions
What the Desidustat Phase III Trial Covers
The trial will be conducted in collaboration with the Indian Council of Medical Research, or ICMR, and is designed as a 203-day study to evaluate the efficacy and safety of Desidustat oral tablets in treating anemia associated with sickle cell disease. The trial will enrol 164 patients diagnosed with the condition, a significant undertaking given the specialised patient population involved.
Zydus Lifesciences share price: Today’s Trading Levels
| Metric | Value |
|---|---|
| Zydus Lifesciences CMP | Rs 1,118.20 |
| Day Change | Down Rs 11.55 or 1.02 percent |
| Intraday Range | Rs 1,106.70 to Rs 1,122.20 |
| Volume Today | 20,855 shares |
| 5 Day Average Volume | 125,979 shares (down 83.45 percent) |
Learn More About Univest, a SEBI Registered Investment Advisor
The Zydus Lifesciences share price traded lower today even as the trial approval was announced, with the stock’s decline likely reflecting broader sector weakness across pharma names rather than a reaction specific to this regulatory milestone, since Phase III trial approvals typically represent a multi-year path to commercialisation rather than an immediate revenue catalyst.
What This Trial Approval Means for Zydus Investors
For investors tracking the Zydus Lifesciences share price, sickle cell disease represents a significant unmet medical need, particularly relevant to India’s tribal and certain regional populations where the condition has notable prevalence. Desidustat is Zydus Lifesciences’ novel oral hypoxia inducible factor prolyl hydroxylase inhibitor, already approved in India for anemia associated with chronic kidney disease, and this new trial explores its potential in an additional indication.
Investors should note that Phase III trials, even when successfully initiated, typically take considerable time to complete and require subsequent regulatory review before any potential commercial launch, meaning the Zydus Lifesciences share price impact from this specific development is likely to play out over a multi-year horizon rather than in the near term.
Zydus Lifesciences operates a diversified pharmaceutical business spanning generics, branded formulations, biosimilars, consumer wellness and specialty products across India and export markets including the United States. The company has also built a growing new chemical entity research pipeline, of which Desidustat and its expanding indications form one part.
Successful new chemical entity development remains a long term value driver for large Indian pharmaceutical companies, since these molecules, once approved, typically carry stronger pricing power and less generic competition than standard formulation products, making pipeline progress an important metric for investors to track over time.
Download the Univest iOS App or Univest Android App to track Zydus Lifesciences share price and clinical trial updates.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Zydus Lifesciences share price in the news today?
Ans. Zydus Lifesciences share price is in the news after the company received approval to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease.
What is the current Zydus Lifesciences share price?
Ans. Zydus Lifesciences share price was quoting at Rs 1,118.20, down Rs 11.55 or 1.02 percent, with an intraday high of Rs 1,122.20 and a low of Rs 1,106.70.
What does the Desidustat Phase III trial involve?
Ans. The trial is a 203-day study conducted with ICMR to evaluate the efficacy and safety of Desidustat oral tablets in treating anemia in sickle cell disease patients, enrolling 164 patients.
What is Desidustat already approved for?
Ans. Desidustat is already approved in India for treating anemia associated with chronic kidney disease, and this new trial explores its use in sickle cell disease.
Why did Zydus Lifesciences share price fall despite the trial approval?
Ans. Zydus Lifesciences share price fell today likely due to broader pharma sector weakness rather than a reaction to the trial approval itself, since Phase III trials represent a long term development path.
Is Zydus Lifesciences share price a buy after this trial approval?
Ans. This article does not constitute investment advice. Investors should assess the company’s broader pipeline and consult a SEBI registered investment advisor before investing.
Where can I track Zydus Lifesciences share price and clinical trial news?
Ans. You can track live Zydus Lifesciences share price movements and clinical trial updates on the Univest app and website.
